Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03674307 · ClinicalTrials.gov registry record · NA
Screening for Asymptomatic Coronary Artery Disease in Kidney Transplant Candidates
A NA study of Cardiovascular Diseases and End Stage Renal Disease, sponsored by University of British Columbia.
- Recruiting
- Registry status
- NA
- Development phase
- 3,306
- Enrollment target
- 20
- Study locations
NCT03674307: Recruiting NA study of Cardiovascular Diseases and End Stage Renal Disease, sponsored by University of British Columbia.
NCT03674307 is a NA study of Cardiovascular Diseases and End Stage Renal Disease that is actively recruiting participants, run by University of British Columbia. The registered enrollment target is 3,306 participants, below the 26,963-participant average among 300 other Cardiovascular Diseases trials with a reported enrollment target (88% lower). The trial reports 20 study locations across 9 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03674307, a NA study of Cardiovascular Diseases and End Stage Renal Disease, is actively recruiting participants, sponsored by University of British Columbia.
- RECRUITING
- Registry status
- NA
- Development phase
- 3,306 participants
- Enrollment target
- 20
- Study locations
Study Summary
The Canadian Australasian Randomized Trial of Screening Kidney Transplant Candidates for Coronary Artery Disease (CARSK) will test the hypothesis that eliminating the regular use of non-invasive screening tests for CAD AFTER waitlist activation is not inferior to regular (i.e., annual) screening for CAD during wait-listing for the prevention of Major Adverse Cardiac Events. Secondary analyses will assess the impact of screening on the rate of transplantation, and the relative cost-effectiveness of screening.
Primary Outcome
Primary efficacy: major adverse cardiac event (MACE), defined as any of the following: cardiovascular death, myocardial infarction, emergency revascularisation, hospitalisation with unstable angina. The outcome will be assessed by: 1. Notification to the transplant coordinators when patients are admitted in hospital (this is the usual standard of care in waitlisted patients). 2. The trial coordinator will gather electronic medical records, letters, procedure notes, and will fill in the relevan
Conditions Studied
Interventions
- OTHER No screening
- OTHER Regular Screening
Study Locations (20)
Ontario
- St. Joseph's Healthcare - Hamilton
- Kingston Health Science Centre - Kingston
- London Health Science Centre - London
- The Ottawa Hospital Research Institute - Ottawa
- University Health Network - Toronto
- St Michael's Hospital - Toronto
Quebec
- CHU de Quebec-Universite Laval's L'Hotel-Dieu de Quebec - Laval
- University of Montreal, Maisonneuve-Rosemont Hospital - Montreal
- McGill University Health Centre - Montreal
- Universite de Montreal, Hopital Maisonneuve-Rosemont - Montreal
Other
- Charité Universitätsmedizin - Berlin
- Sussex Brighton R&D - Brighton
- King's College Hospital NHS Foundation Trust - Brixton
- Epsom and St Helier University Hospitals NHS Trust - Carshalton
Arizona
- University of Arizona - Tucson
District of Columbia
- The George Washington University - Washington D.C.
Alberta
- University of Alberta - Edmonton
British Columbia
- University of British Columbia - Vancouver
Nova Scotia
- Dalhousie University - Halifax
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 3,306 participants |
| Start Date | 2018-12-01 |
| Est. Completion | 2025-12-31 |
| Phase | NA |
What NCT03674307 shows while recruiting
NCT03674307 is an interventional study that assigns participants to a tested intervention. Its 3,306 participants enrollment target places it among the larger protocols in the corpus, below the 26,963-participant average among 300 other Cardiovascular Diseases trials with a reported enrollment target (88% lower).
The record links to 4 conditions, with Cardiovascular Diseases appearing as the primary indexed condition, and to 2 interventions - of which No screening is the first listed.
NCT03674307 names 20 study sites across 9 states, led by Ontario, Quebec, Other.
Frequently Asked Questions
What is clinical trial NCT03674307 about?
NCT03674307 is a clinical study titled "Screening for Asymptomatic Coronary Artery Disease in Kidney Transplant Candidates". The Canadian Australasian Randomized Trial of Screening Kidney Transplant Candidates for Coronary Artery Disease (CARSK) will test the hypothesis that eliminating the regular use of non-invasive screening tests for CAD AFTER waitlist activation is not inferior to regular (i.e., annual) screening for...
What is the current status of trial NCT03674307?
This trial is currently recruiting. It is a NA study. The enrollment target is 3,306 participants. The study started on 2018-12-01. Estimated completion is 2025-12-31.
What conditions does trial NCT03674307 study?
This clinical trial studies the following conditions: Cardiovascular Diseases, End Stage Renal Disease, Kidney Transplantation, Dialysis Related Complication.
What interventions are being tested in trial NCT03674307?
The interventions under investigation include: No screening (OTHER), Regular Screening (OTHER).
Who is sponsoring clinical trial NCT03674307?
This trial is sponsored by University of British Columbia, which has 18 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03674307 being conducted?
This trial has 20 study locations across Arizona, District of Columbia, Alberta, British Columbia, Nova Scotia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Cardiovascular Diseases
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT03674307's enrollment target sits among peer trials
3,306 29th of 300 higher than 272 of 300 other Cardiovascular Diseases trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Cardiovascular Diseases trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
The Influence of Chardonnay Marc Intake on Gut and Cardiometabolic Health
RECRUITING · NA
-
Identifying Strategies to Reduce Cardiovascular Risk Among Mothers of Young Children
RECRUITING · NA
-
Insomnia Treatment and Cardiometabolic Health in Older Adults With Posttraumatic Stress Disorder
RECRUITING · NA
-
Deep Brain Stimulation Motor Ventral Thalamus (VOP/VIM) for Restoration of Speech and Upper-limb Function in People With Subcortical Stroke
RECRUITING · NA
-
Effects of Whole vs. Nonfat Milk Consumption on Body Composition in Children
RECRUITING · NA
-
MagicTouch for Treatment of In-Stent Restenosis in Coronary Artery Lesions
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT07214610 · 3,300 participants · NA
Integrating Biological, Clinical, and Behavioral Factors to Improve Breast Cancer Outcomes - Carolina Breast Cancer Study
- NCT06815536 · 3,291 participants
Master Protocol for Evaluating Multiple Infection Diagnostics for Ciprofloxacin-Resistant Neisseria Gonorrhoeae
- NCT06543446 · 3,290 participants · NA
Comparative Effectiveness of Prophylactic ICD Versus Non-ICD Therapy
- NCT04077762 · 3,266 participants · NA
Radial Vs. State-Of-The-Art Femoral Access for Bleeding and Access Site Complication Reduction in Cardiac Catheterization (REBIRTH)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI